Insider Transactions in Q1 2025 at Altimmune, Inc. (ALT)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2025
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,282
-2.28%
|
$49,692
$6.64 P/Share
|
|
Feb 02
2025
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,950
+4.96%
|
-
|
|
Feb 02
2025
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,708
-3.2%
|
$16,248
$6.64 P/Share
|
|
Feb 02
2025
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+8.42%
|
-
|
|
Feb 02
2025
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,316
-3.07%
|
$13,896
$6.64 P/Share
|
|
Feb 02
2025
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+9.33%
|
-
|
|
Feb 01
2025
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,231
-2.06%
|
$43,386
$6.64 P/Share
|
|
Feb 01
2025
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,545
+4.49%
|
-
|
|
Feb 01
2025
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,109
-2.67%
|
$12,654
$6.64 P/Share
|
|
Feb 01
2025
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+7.25%
|
-
|
|
Feb 01
2025
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-2.59%
|
$10,806
$6.64 P/Share
|
|
Feb 01
2025
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+8.14%
|
-
|
|
Jan 31
2025
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,105
+1.21%
|
$20,525
$5.18 P/Share
|
|
Jan 31
2025
|
Raymond M Jordt Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,614
+6.97%
|
$13,070
$5.18 P/Share
|
|
Jan 31
2025
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,905
+2.55%
|
$9,525
$5.18 P/Share
|
|
Jan 31
2025
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,184
+4.78%
|
$15,920
$5.18 P/Share
|
|
Jan 30
2025
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,701
-3.41%
|
$81,907
$7.0 P/Share
|
|
Jan 30
2025
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,775
+7.25%
|
-
|
|
Jan 30
2025
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,173
-4.29%
|
$22,211
$7.0 P/Share
|
|
Jan 30
2025
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+11.14%
|
-
|
|
Jan 30
2025
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,709
-4.31%
|
$18,963
$7.0 P/Share
|
|
Jan 30
2025
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+12.85%
|
-
|
|
Jan 25
2025
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,994
-7.16%
|
$29,964
$6.98 P/Share
|
|
Jan 25
2025
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,600
+17.32%
|
-
|
|
Jan 25
2025
|
Raymond M Jordt Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,862
-10.68%
|
$23,172
$6.98 P/Share
|
|
Jan 25
2025
|
Raymond M Jordt Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,600
+28.77%
|
-
|
|
Jan 25
2025
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,264
-7.36%
|
$25,584
$6.98 P/Share
|
|
Jan 25
2025
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,600
+20.14%
|
-
|
|
Jan 25
2025
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,157
-5.44%
|
$108,942
$6.98 P/Share
|
|
Jan 25
2025
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,050
+11.18%
|
-
|
|
Jan 01
2025
|
Raymond M Jordt Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,485
-10.34%
|
$17,395
$7.21 P/Share
|
|
Jan 01
2025
|
Raymond M Jordt Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+28.06%
|
-
|